Search Results - "Madhu, Chaudhry"

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial by Cescon, David W, Nowecki, Zbigniew, Gallardo, Carlos, Holgado, Esther, Iwata, Hiroji, Masuda, Norikazu, Otero, Marco Torregroza, Loi, Sherene, Guo, Zifang, Gonzalo, Gomez Abuin, Diego, Kaen, Matias, Molina, Stephen, Begbie, Philip, Clingan, Sherene, Loi, Dhanusha, Sabanathan, Donatienne, Taylor, Domicio Carvalho, Lacerda, Fernando Cezar Toniazzi, Lissa, Felipe, Silva, Joanne, Yu, Alejandro, Acevedo, Bohuslav, Melichar, Katarina, Petrakova, Jana, Prausova, Erik, Jakobsen, Jeanette, Jensen, Soren, Linnet, Tamas, Lorincz, Herve, Bonnefoi, Isabelle, Desmoulins, Jens-Uwe, Blohmer, Nadia, Harbeck, Jens, Huober, Christian, Kurbacher, Sibylle, Loibl, Tibor, Csoszi, Zsuzsanna, Kahan, Karoly, Mahr, John, Crown, Seamus, O'Reilly, Takaaki, Fujii, Hiroji, Iwata, Hirofumi, Mukai, Seigo, Nakamura, Shoichiro, Ohtani, Akihiko, Osaki, Yasuaki, Sagara, Masato, Takahashi, Koichiro, Tsugawa, Junichiro, Watanabe, Yutaka, Yamamoto, Teruo, Yamauchi, Angel, Gomez Villanueva, Alejandro, Juarez Ramiro, Flavia, Morales-Vasquez, David, Porter, Ewa, Chmielowska, Ewa, Nowakowska-Zajdel, Zbigniew, Nowecki, Barbara, Radecka, Joanna, Streb, Alexander, Arkhipov, Natalia, Fadeeva, Oleg, Lipatov, Kwong Hwa, Park, Yeon Hee, Park, Begona, Bermejo de las Heras, Javier, Cortes, Luis, de la Cruz Merino, Jose, Garcia Saenz, Maria, Gion, Mei-Ching, Liu, Chiun-Sheng, Huang, Cagatay, Arslan, Irfan, Cicin, Erhan, Gokmen, Ozgur, Ozyilkan, Sinan, Yavuz, Janine, Graham, Mark, Tuthill, Christopher, Twelves, Duncan, Wheatley, Oleksii, Kolesnik, Olena, Kolesnik, Alla, Nasonova, Olga, Ponomarova, Dmytro, Trukhin, Sibel, Blau, Madhu, Chaudhry, Scott, Cole, William, Irvin, Randa, Loutfi, Janice, Lu, Coral, Omene, Timothy, Panella, Michael, Schleider, Robert, Siegel, Michael, Simon, Frances, Valdes-Albini

“…Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to…”
Get full text

The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial by Santa-Maria, Cesar A, Coughlin, Janelle W, Sharma, Dipali, Armanios, Mary, Blackford, Amanda L, Schreyer, Colleen, Dalcin, Arlene, Carpenter, Ashley, Jerome, Gerald J, Armstrong, Deborah K, Chaudhry, Madhu, Cohen, Gary I, Connolly, Roisin M, Fetting, John, Miller, Robert S, Smith, Karen L, Snyder, Claire, Wolfe, Andrew, Wolff, Antonio C, Huang, Chiung-Yu, Appel, Lawrence J, Stearns, Vered

“…We initiated a clinical trial to determine the proportion of breast cancer survivors achieving ≥5% weight loss using a remotely delivered weight loss…”
Get full text

Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP) by Turner, Nicholas, Saura, Cristina, Aftimos, Philippe, van den Tweel, Evelyn, Oesterholt, Mayke, Koper, Norbert, Colleoni, Marco, Kaczmarek, Emilie, Punie, Kevin, Song, Xinni, Armstrong, Anne, Bianchi, Giulia, Stradella, Agostina, Ladoire, Sylvain, Lim, Joline Si Jing, Quenel-Tueux, Nathalie, Tan, Tira J, Escrivá-de-Romaní, Santiago, O'Shaughnessy, Joyce

“…Human epidermal growth factor receptor 2 (HER2)-targeted therapy is standard of care for HER2-positive (HER2+) breast cancer, but most patients develop…”
Get full text

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY by Balmaña, Judith, Fasching, Peter A., Couch, Fergus J., Delaloge, Suzette, Labidi-Galy, Intidhar, O’Shaughnessy, Joyce, Park, Yeon Hee, Eisen, Andrea F., You, Benoit, Bourgeois, Hughes, Gonçalves, Anthony, Kemp, Zoe, Swampillai, Angela, Jankowski, Tomasz, Sohn, Joo Hyuk, Poddubskaya, Elena, Mukhametshina, Guzel, Aksoy, Sercan, Timcheva, Constanta V., Park-Simon, Tjoung-Won, Antón-Torres, Antonio, John, Ellie, Baria, Katherine, Gibson, Isabel, Gelmon, Karen A.

“…Purpose The interim analysis of the phase IIIb LUCY trial demonstrated the clinical effectiveness of olaparib in patients with germline BRCA-mutated (gBRCAm),…”
Get full text

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial by Richardson, Paul G, Legieć, Wojciech, Larocca, Alessandra, Reece, Donna, Špička, Ivan, Ganetsky, Alex, Popa McKiver, Mihaela, Lonial, Sagar, Dimopoulos, Meletios A, Bahlis, Nizar J, Beksaç, Meral, Petrucci, Maria T, Mateos, María-Victoria, Špička, Ivan, Kaufman, Jonathan L, Lonial, Sagar, Podhorecka, Monika, Besemer, Britta, De Fabritiis, Paolo, Emanuele, Angelucci, Bladé, Joan, Casado, Luis F, Panelli, Victoria, Benson, Don, Reeves, James, Lech-Marańda, Ewa, Acs, Peter, De Prijck, Bernard, Sebag, Michael, Modiano, Manuel, Wright, Matthew P, Vekemans, Marie-Christine, Gutiérrez, María AE, Driessen, Christoph, Behl, Rajesh, Moezi, Mehdi, Cortes, Hector V, Horvath, Noemi, D'Rozario, James M, Latimer, Maya, Mittelman, Moshe, Vacca, Angelo, Jędrzejczak, Wiesław W, Robak, Tadeusz, Ruiz, Marco, Alencar, Alvaro, Kasbari, Samer, Cohen, Gary, Jakubowiak, Andrzej, Rosenbaum, Cara, Delforge, Michel, Demuynck, Hilde, Schots, Rik, Blau, Igor W, Dürk, Heinz A, Munder, Markus, Scheid, Christof, Symeonidis, Argiris S, Illés, Árpád, Coyne, Mark, O'Gorman, Peter, Hayden, Patrick, Ben-Yehuda, Dina, Braester, Andrei, Lugassy, Gilles, Bosi, Alberto, Pezzatti, Sara, Pogliani, Enrico M, Goñi, María A, Carboneras, Ana V, Rubenstein, S. Eric, Khojasteh, Ali, Liman, Andrew, Stockerl-Goldstein, Keith, Strnad, Charles, Stuart, Robert, Jhangiani, Haresh, Filshie, Robin, Hertzberg, Mark S, Kotb, Rami, Mügge, Lars-Olof, Kyriakou, Despoina, Clotilde, Cangialosi, Musuraca, Gerardo, Vladareanu, Ana-Maria, Encinas, Cristina, Gayoso, Jorge, Pabst, Thomas, Rabin, Neil, Sahovic, Entezam, Khasawneh, Mohamad, Sehgal, Rajesh, Lunning, Matthew, Vose, Julie, Faber, Edward, MacFarlane, Donald, Hohl, Raymond, Mahmood, Tariq, Bhaskar, Birbal, Richard, Robert

“…Elotuzumab plus lenalidomide and dexamethasone has shown improved progression-free and overall survival versus lenalidomide and dexamethasone in patients with…”
Get full text